IPF lung disease numbers are rising quickly to become a significant cause of mortality in UK

April 28, 2011, British Medical Journal

The number of cases of idiopathic pulmonary fibrosis (IPF) has continued to rise significantly in the first decade of the 21st century and could lead to more deaths than ovarian cancer, lymphoma, leukaemia, or kidney cancer, reveals research published ahead of print in the Thorax journal.

IPF is the most common of the pneumonias that happen without an apparent cause and previous studies have shown that incidence and deaths from the disease are rising in the UK and the USA.

However, there is currently no mandatory registration of IPF diagnoses in the UK or anywhere else in the world.

Researchers from the Nottingham Respiratory Biomedical Research Unit and the University of Nottingham set out to determine the trends in incidence of this disease.

The researchers used two different sets of data to investigate whether the incidence of pulmonary fibrosis in the 21st century was still growing in the UK.

These data were routine from the Office for National Statistics (ONS) between 1968 and 2008 and The Health Improvement Network (THIN), a computerised longitudinal primary care database recorded by UK GPs in 446 general practices.

Using the definition of idiopathic clinical syndrome (IPF-CS), they found that there were 56,675 deaths attributed to IPF-CS in England and Wales from 1968 to 2008. The number of recorded deaths increased from 479 in 1968 to 3,019 in 2008.

Annual death certificate recordings of the disease rose six-fold across the study period from 0.92 per 100,000 people in the 1968-1972 period, to 5.1 per 100,000 people in the 2006-2008 period.

Numbers of cases recorded in primary care rose by 35% from 2000 to 2008 with an overall incidence rate of 7.44 per 100,000 person years. Incidence was highest in men, the older population and in north-west England.

Using these figures, the researchers estimate that there are currently around 15,000 people in the UK with a diagnosis of the disease, and that 5,000 new cases will be diagnosed each year, with around 5,000 people with the disease dying.

This would mean more people in the UK dying each year from IPF-CS than from , lymphoma, , mesothelioma or .

The authors conclude: " At the moment, we do not understand what causes IPF-CS, why the incidence is on the rise or how best to treat individuals with this disease spectrum.

"It is clear that IPF-CS is an important public health problem and warrants more research investment."

Related Stories

Recommended for you

Antifungal agent found to be possible treatment for porphyria

September 24, 2018
A large team of researchers from Spain, France and the U.S. has found that a common antifungal agent might be useful as a treatment for a rare type of porphyria. In their paper published in the journal Science Translational ...

New findings on the muscle disease Laing early-onset distal myopathy

September 24, 2018
New avenues are now being opened toward treatment of Laing distal myopathy, a rare disorder that causes atrophy of the muscles in the feet, hands and elsewhere. In a study published in the journal PNAS, researchers have identified ...

Insulin shows great potential against chronic colitis

September 24, 2018
Diabetes is not the only disease on which insulin has an effect, it appears. In a new study using tests on mice, researchers from the University of Copenhagen, among others, have discovered a new method for treating chronic ...

A new approach to developing a vaccine against vivax malaria

September 21, 2018
A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, ...

Pre-clinical success for a universal flu vaccine offers hope for third generation approach

September 21, 2018
Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.

Researchers define possible molecular pathway for neurodegeneration in prion diseases

September 21, 2018
A new study has shed light on the mechanisms underlying the progression of prion diseases and identified a potential target for treatment.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.